Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
**Background:** Docetaxel has been a standard of care for castration-resistant prostate cancer (CRPC) in the United States since 2004, yet little has been reported on its patterns of use in routine practice. To help understand these patterns, a retrospective study was conducted and is reported here....
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | http://jheor.scholasticahq.com/article/9894-real-world-treatment-patterns-in-men-with-castration-resistant-prostate-cancer-receiving-docetaxel.pdf |